Clinical Trial Update: The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating NC318 alone or in combination with pembrolizumab in adults with advanced non-small cell lung cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• NC318
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Yale University | Conditions: Advanced Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING